Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Cybin Announces Oversubscribed Private Placement of U.S. $150 Million
https://ir.cybin.com/investors/news/news-details/2024/Announces-Oversubscribed-Private-Placement-of-U.S.-150-Million/default.aspx
$CYBN Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder
https://www.businesswire.com/news/home/20240123732289/en/Cybin-Announces-FDA-Clearance-to-Initiate-a-Phase-2a-Study-of-CYB004-in-Generalized-Anxiety-Disorder
CYBN Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder https://www.businesswire.com/news/home/20240123732289/en/Cybin-Announces-FDA-Clearance-to-Initiate-a-Phase-2a-Study-of-CYB004-in-Generalized-Anxiety-Disorder
$CYBN huge breakthrough in psychiatry! Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses
https://www.businesswire.com/news/home/20231130470838/en/Cybin-Reports-Positive-Topline-Data-from-Phase-2-Study-of-CYB003-in-Major-Depressive-Disorder-with-79-of-Patients-in-Remission-after-Two-12mg-Doses
$CYBN Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses
A recent study found that a single dose of CYB003 dramatically reduced depression symptoms, and a second dose further improved outcomes. The study's primary goal was met with an average 14-point drop in the Montgomery-Asberg Depression Rating Scale (MADRS) for those taking CYB003 (12mg) compared to placebo, showing significant improvement after three weeks. By six weeks, further reductions in MADRS scores were noted, with 79% of participants effectively in remission from depression after two doses of CYB003 (12mg). The drug was well-tolerated with no serious side effects at doses of 12mg and 16mg.
The Company to host CYB003 Topline Depression Study Review and R&D Briefing today at 10:00am ET in New York City
LINK [https://ir.cybin.com/investors/news/news-details/2023/Cybin-Reports-Positive-Topline-Data-from-Phase-2-Study-of-CYB003-in-Major-Depressive-Disorder-with-79-of-Patients-in-Remission-after-Two-12mg-Doses/default.aspx]
$CYBN breakthrough data, Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses
https://www.businesswire.com/news/home/20231130470838/en/Cybin-Reports-Positive-Topline-Data-from-Phase-2-Study-of-CYB003-in-Major-Depressive-Disorder-with-79-of-Patients-in-Remission-after-Two-12mg-Doses
HUGE RESULTS. Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses
https://www.businesswire.com/news/home/20231130470838/en/Cybin-Reports-Positive-Topline-Data-from-Phase-2-Study-of-CYB003-in-Major-Depressive-Disorder-with-79-of-Patients-in-Remission-after-Two-12mg-Doses
Unveiling Cybin's ($CYBN) Strategic Move: Talking Small Pharma Acquisition with CEO Doug Drysdale
Watch the interview here:
Unveiling Cybin's ($CYBN) Strategic Move: Talking Small Pharma Acquisition with CEO Doug Drysdale
Unveiling Cybin's ($CYBN) Strategic Move: Talking Small Pharma Acquisition with CEO Doug Drysdale
Watch here:
Watch the interview: Unveiling Cybin's ($CYBN) Strategic Move: Talking Small Pharma Acquisition with CEO Doug Drysdale
$CYBN acquires Small Pharma Inc.
https://ir.cybin.com/investors/news/news-details/2023/Cybin-to-Acquire-Small-Pharma-Inc/default.aspx
$CYBN to Acquire Small Pharma Inc.
https://ir.cybin.com/investors/news/news-details/2023/Cybin-to-Acquire-Small-Pharma-Inc/default.aspx
$CYBN's acquisition of Small Pharma makes it a global leader in psychedelic drug development!!
https://ir.cybin.com/investors/news/news-details/2023/Cybin-to-Acquire-Small-Pharma-Inc/default.aspx
$CYBN +21% today!
$CYBN up 21% this morning!!
$CYBN Why Cybin Could Be Set For Greater Opportunities This Year - Trade to Black
$CYBN CAD$41M Share Purchase Commitment Fuels Progress in Psychedelic Medicine
https://nyweekly.com/business/cybins-share-purchase-commitment-fuels-progress/
$CYBN Cybin’s CAD$41M Share Purchase Commitment Fuels Progress in Psychedelic Medicine
https://nyweekly.com/business/cybins-share-purchase-commitment-fuels-progress/
Investing in Innovation, Cybin’s CAD$41M Share Purchase Commitment Fuels Progress in Psychedelic Medicine
https://nyweekly.com/business/cybins-share-purchase-commitment-fuels-progress/
$CYBN Investing in Innovation, Cybin’s CAD$41M Share Purchase Commitment Fuels Progress in Psychedelic Medicine
https://nyweekly.com/business/cybins-share-purchase-commitment-fuels-progress/
$CYBN Cybin Announces US$30M Common Stock Purchase Agreement from Lincoln Park Capital Fund
https://ir.cybin.com/investors/news/news-details/2023/Cybin-Announces-US30M-Common-Stock-Purchase-Agreement-from-Lincoln-Park-Capital-Fund/default.aspx
Cybin $CYBN Announces US$30M Common Stock Purchase Agreement from Lincoln Park Capital Fund
https://www.businesswire.com/news/home/20230530005628/en/Cybin-Announces-US30M-Common-Stock-Purchase-Agreement-from-Lincoln-Park-Capital-Fund
$CYBN BREAKING: Cybin Announces US$30M Common Stock Purchase Agreement from Lincoln Park Capital Fund
https://www.businesswire.com/news/home/20230530005628/en/Cybin-Announces-US30M-Common-Stock-Purchase-Agreement-from-Lincoln-Park-Capital-Fund
Cybin Announces US$30M Common Stock Purchase Agreement from Lincoln Park Capital Fund
https://www.businesswire.com/news/home/20230530005628/en/Cybin-Announces-US30M-Common-Stock-Purchase-Agreement-from-Lincoln-Park-Capital-Fund
$CYBN Cybin Announces US$30M Common Stock Purchase Agreement from Lincoln Park Capital Fund
https://www.businesswire.com/news/home/20230530005628/en/Cybin-Announces-US30M-Common-Stock-Purchase-Agreement-from-Lincoln-Park-Capital-Fund
$CYBN NEWS: Cybin Initiates First-in-Human Dosing of CYB004 in Phase 1 Clinical Trial
https://www.businesswire.com/news/home/20230524005312/en/Cybin-Initiates-First-in-Human-Dosing-of-CYB004-in-Phase-1-Clinical-Trial
$CYBN Initiates First-in-Human Dosing of CYB004 in Phase 1 Clinical Trial
https://www.businesswire.com/news/home/20230524005312/en/Cybin-Initiates-First-in-Human-Dosing-of-CYB004-in-Phase-1-Clinical-Trial
$CYBN BREAKING: Cybin Initiates First-in-Human Dosing of CYB004 in Phase 1 Clinical Trial
https://www.businesswire.com/news/home/20230524005312/en/Cybin-Initiates-First-in-Human-Dosing-of-CYB004-in-Phase-1-Clinical-Trial
$CYBN Cybin Initiates First-in-Human Dosing of CYB004 in Phase 1 Clinical Trial!
https://www.businesswire.com/news/home/20230524005312/en/Cybin-Initiates-First-in-Human-Dosing-of-CYB004-in-Phase-1-Clinical-Trial
$CYBN Cybin Initiates First-in-Human Dosing of CYB004 in Phase 1 Clinical Trial
https://www.businesswire.com/news/home/20230524005312/en/Cybin-Initiates-First-in-Human-Dosing-of-CYB004-in-Phase-1-Clinical-Trial
$CYBN Announces Last Subject Dosed in Part B of its Phase 1 CYB004-E Trial
https://ir.cybin.com/investors/news/news-details/2023/Cybin-Announces-Last-Subject-Dosed-in-Part-B-of-its-Phase-1-CYB004-E-Trial/default.aspx
$CYBN Cybin Announces Last Subject Dosed in Part B of its Phase 1 CYB004-E Trial
https://ir.cybin.com/investors/news/news-details/2023/Cybin-Announces-Last-Subject-Dosed-in-Part-B-of-its-Phase-1-CYB004-E-Trial/default.aspx
Cybin Announces Last Subject Dosed in Part B of its Phase 1 CYB004-E Trial
https://ir.cybin.com/investors/news/news-details/2023/Cybin-Announces-Last-Subject-Dosed-in-Part-B-of-its-Phase-1-CYB004-E-Trial/default.aspx
Going to break out, positive news and canaccord genuity $7PT
$CYBN BREAKING: CYBIN Announces Positive Data from its CYB003 Phase 1/2a Trial and Provides Update on its CYB004 Development Program
Canaccord Genuity $7PT https://canaccordgenuity.bluematrix.com/sellside/EmailDocViewer?encrypt=3f15ecfa-d7c5-4404-9d1f-7fc780d657d8&mime=pdf&co=Canaccordgenuity&id
https://www.businesswire.com/news/home/20230228005438/en/Cybin-Announces-Positive-Data-from-its-CYB003-Phase-12a-Trial-and-Provides-Update-on-its-CYB004-Development-Program
$CYBN BREAKING NEWS CYBIN Announces Positive Data from its CYB003 Phase 1/2a Trial and Provides Update on its CYB004 Development Program
https://www.businesswire.com/news/home/20230228005438/en/Cybin-Announces-Positive-Data-from-its-CYB003-Phase-12a-Trial-and-Provides-Update-on-its-CYB004-Development-Program
$CYBN the R&D day event today promises to deliver critical updates on Cybin's research and development efforts, most notably the cutting-edge CYB003 clinical trials, which, if approved, would become the first FDA-approved psychedelic drug for treating major depressive disorder and unlock tremendous growth potential.
Watch here: https://ir.cybin.com/investors/events-and-presentations/events/event-details/2023/Cybin-Virtual-RD-Day-2023-Innovating-New-Treatment-Approaches-for-Mental-Healthcare-2023-nICt-kZDwl/default.aspx
DD: https://canaccordgenuity.bluematrix.com/sellside/EmailDocViewer?encrypt=3f15ecfa-d7c5-4404-9d1f-7fc780d657d8&mime=pdf&co=Canaccordgenuity&id
Canaccord Genuity says $CYBN’s R&D event today will be pivotal for the company and it’s shareholders, $7 PT
https://canaccordgenuity.bluematrix.com/sellside/EmailDocViewer?encrypt=3f15ecfa-d7c5-4404-9d1f-7fc780d657d8&mime=pdf&co=Canaccordgenuity&id
Watch here: https://ir.cybin.com/investors/events-and-presentations/events/event-details/2023/Cybin-Virtual-RD-Day-2023-Innovating-New-Treatment-Approaches-for-Mental-Healthcare-2023-nICt-kZDwl/default.aspx
$CYBN Cannacord Genuity says Cybin’s R&D event today at 10AM EST will be pivotal for the company, $7PT
https://canaccordgenuity.bluematrix.com/sellside/EmailDocViewer?encrypt=3f15ecfa-d7c5-4404-9d1f-7fc780d657d8&mime=pdf&co=Canaccordgenuity&id
Watch the event: https://ir.cybin.com/investors/events-and-presentations/events/event-details/2023/Cybin-Virtual-RD-Day-2023-Innovating-New-Treatment-Approaches-for-Mental-Healthcare-2023-nICt-kZDwl/default.aspx